Psoriasis is a chronic inflammatory disease characterised by sharply demarcated
erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by …

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background & Aims Guselkumab, a selective p19 interleukin-23 antagonist, is approved for
the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease
characterized by thickened, red, scaly plaques and systemic inflammation. Psoriasis is also …

Psoriasis is caused by a complex interplay between the immune system, psoriasis-
associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last …

Abstract IL-12 and IL-23 are closely related cytokines with important roles in the regulation of
tissue inflammation. Converging evidence from studies in mice, human observational …

The balance between Th17 cells and regulatory T cells (Tregs) has emerged as a prominent
factor in regulating autoimmunity and cancer. Th17 cells are vital for host defense against …

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with
awareness and attention to comorbidities - ScienceDirect Skip to main contentSkip to article …

Importance Drug survival of biologic therapies for psoriasis is a proxy for longer-term
treatment effectiveness and safety. Patient factors that are associated with the survival of …